Roche, which is already working with Poseida Therapeutics to develop off-the-shelf cell therapies for blood cancers, is broadening its ambitions to incorporate the modality with a deal to amass the biotech for $1 billion upfront. Making use of allogeneic cell therapies to stable tumors and immunological indications are among the many targets Roche goals to realize by buying San Diego-based […]